semaglutide news 2025 A network meta-analysis backed weight-loss benefits with several GLP-1 receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio FDA declares end to Wegovy
Description
Jama, 324(1), 79-89
doi: 10.14740/jocmr3647
For anyone left stranded by todays ending of mass compounded semaglutide, this is certainly a gesture by Novo Nordisk (they could have offered nothing), but it feels more like a bone being thrown to the masses
Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, et al
